Sign In
Buy IMGN
$31.23
+0 (+0%)
At Close: May 08, 2024
Can Humana's (HUM) Q4 Earnings Beat on Healthcare Services?
02:43pm, Monday, 30'th Jan 2023 Zacks Investment Research
Humana's (HUM) fourth-quarter results are likely to reflect surging Healthcare Services profits on strong pharmacy business.
HCA Healthcare (HCA) to Post Q4 Earnings: What's in the Cards?
03:59pm, Tuesday, 24'th Jan 2023 Zacks Investment Research
HCA Healthcare's (HCA) fourth-quarter results are likely to reflect increased equivalent admissions and outpatient surgery cases.
Analyst Ratings for Immunogen
08:01pm, Monday, 23'rd Jan 2023 Benzinga
Analysts have provided the following ratings for Immunogen (NASDAQ:IMGN) within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
4
2
1
0
0
Last
Elevance Health (ELV) to Post Q4 Earnings: What to Expect
01:57pm, Monday, 23'rd Jan 2023 Zacks Investment Research
Elevance Health's (ELV) fourth-quarter results are likely to reflect higher premiums, Commercial & Specialty Business' sales and total expenses.
Aurinia (AUPH) Soars 37.5%: Is Further Upside Left in the Stock?
09:47am, Wednesday, 04'th Jan 2023 Zacks Investment Research
Aurinia (AUPH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the roa
Analyst Ratings for Immunogen
07:00pm, Friday, 30'th Dec 2022 Benzinga
Analysts have provided the following ratings for Immunogen (NASDAQ:IMGN) within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
4
2
0
0
0
Last
Futu Holdings, UP Fintech Holding And Some Other Big Stocks Moving Lower On Friday
04:09pm, Friday, 30'th Dec 2022 Benzinga
U.S. stocks traded lower, with the Dow Jones dropping over 200 points on Friday. Here are some big stocks recording losses in today’s session.
Futu Holdings Limited (NASDAQ: FUTU) shares dipped 24.
6 Analysts Have This to Say About Immunogen
04:01pm, Friday, 30'th Dec 2022 Benzinga
Over the past 3 months, 6 analysts have published their opinion on Immunogen (NASDAQ:IMGN) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a compa
What 6 Analyst Ratings Have To Say About Immunogen
03:02pm, Friday, 30'th Dec 2022 Benzinga
Analysts have provided the following ratings for Immunogen (NASDAQ:IMGN) within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
4
2
0
0
0
Last
Ardelyx To Rally 160%? Here Are 10 Other Price Target Changes For Friday
03:01pm, Friday, 30'th Dec 2022 Benzinga
Citigroup raised Ardelyx, Inc. (NASDAQ: ARDX) price target from $6 to $7. Citigroup analyst Yigal Nochomovitz maintained a Buy rating on the stock. Ardelyx shares rose 9.4% to $2.7685 on Friday.
H
Company News for Dec 30, 2022
02:30pm, Friday, 30'th Dec 2022 Zacks Investment Research
Companies in The News Are: IMGN, TGTX, TSLA, MSFT
ImmunoGen's Newly Approved Ovarian Cancer Drug Listed As Preferred Regime
05:56pm, Wednesday, 28'th Dec 2022 Benzinga
The National Comprehensive Cancer Network (NCCN) released new guidelines for ovarian cancer treatment, which include ImmunoGen Inc's (NASDAQ: IMGN) Elahere (mirvetuximab soravtansine-gynx) as a pref
Gilead (GILD) To Get Full Rights for Jounce's Immunotherapy
03:59pm, Wednesday, 28'th Dec 2022 Zacks Investment Research
Gilead Sciences (GILD) is set to buy the remaining rights to the potential first-in-class immunotherapy GS-181 from Jounce Therapeutics.
ImmunoGen Announces Webcast of Presentation and Q&A at the 41st Annual J.P. Morgan Healthcare Conference
04:30pm, Tuesday, 27'th Dec 2022
WALTHAM, Mass.--( BUSINESS WIRE )--ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Mark Enyedy, Pre
Gilead (GILD) Partners With Arcellx, ImmunoGen in Oncology
03:55pm, Monday, 12'th Dec 2022 Zacks Investment Research
Gilead (GILD) announces deals with Arcellx, Inc. and ImmunoGen to strengthen its oncology pipeline.
